Video

How High Cost Oncology Drugs Are Changing Specialty Pharmacy

Author(s):

Lauren Santye, Assistant Editor

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses the impact of oncology medications and how specialty pharmacies can adjust.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses the impact of oncology medications and how specialty pharmacies can adjust.

Related Videos
Related Content
AACR 2025: Liposomal Annamycin May Enhance Chemotherapy Efficacy Across Hematologic and Solid Tumors
May 1st 2025

AACR 2025: Liposomal Annamycin May Enhance Chemotherapy Efficacy Across Hematologic and Solid Tumors

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Molecular model of pembrolizumab | Image Credit: © Dr_Microbe - stock.adobe.com
May 1st 2025

Neoadjuvant Pembrolizumab May Redefine Standard of Care in Locally Advanced Head and Neck Cancer

Alexandra Gerlach, Associate Editor
Antibody Drug Conjugates and Breast Cancer: Insights from a Pharmacy Times Peer Exchange
April 14th 2025

Antibody Drug Conjugates and Breast Cancer: Insights from a Pharmacy Times Peer Exchange

Alexandra Gerlach, Associate Editor
Stethoscope and heart-shaped stress toy on counter -- Image credit: Katsiaryna | stock.adobe.com
May 1st 2025

Expert Q&A: A Pharmacist's Perspective on Collaborating for Better Heart Health

Gillian McGovern, Associate Editor Kelly Rubi, PharmD, CPh, BCPS, BCACP
Health insurance, tax concept on blue background
May 1st 2025

Asembia AXS25: Patients Desire Education and Thorough Resources to Better Navigate Health Plans

Luke Halpern, Assistant Editor